LongBio Pharma Sets 21 August 2026 Board Meeting to Review 1H26 Results and Potential Dividend
Bulletin Express
Aug 11
LongBio Pharma (Suzhou) Co., Ltd. has scheduled a board meeting for Friday, 21 August 2026. The agenda includes approval of the unaudited interim results for the six months ended 30 June 2026 and consideration of an interim dividend distribution.
The announcement, dated 11 August 2026, confirms that any dividend decision will be determined at the upcoming session.
As of the announcement date, the Board comprises 11 directors: three executive directors (Dr. Liu Heng, Dr. Sun Bill Nai-chau and Mr. Xie Ming), four non-executive directors (Mr. Lin Jian, Ms. Gu Qin, Dr. Xue Di and Dr. Chen Kan) and four independent non-executive directors (Mr. Siu Paul Yu Hay, Mr. Ruan Tim, Mr. Yang Chun and Mr. Zhou Guofang).
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.